Lombard Medical Reports First Half and Third Quarter 2017 Financial Results

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms (AAA), today reported unaudited year-to-date financial results for the first nine months ended September 30, 2017. 2017 Operational Highlights Appointment of Kurt Lemvigh as CEO, April 2017 Appointment of Richard Peace as Finance Director, May 2017 Appointment of Jonathan Hornsby as Vice President, Sales & Marke...

Lombard Medical Announces Shares to Trade on OTCQX

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (Nasdaq: EVAR), a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms (AAA), today announced that it has notified Nasdaq of its intention to voluntarily delist the Company’s shares from the Nasdaq Capital Market (“Nasdaq”) and transfer its listing to the OTCQX. Lombard anticipates that its common shares will trade under its existing ticker symbol EVAR on the OTCQX Market effective as of the market open on November 9, 2017. ...

Lombard Medical Announces First Patient Enrolled and Treated in the ALTITUDE Registry for the Altura® Stent Graft System

OXFORDSHIRE, U.K.--(BUSINESS WIRE)-- Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System. The ALTITUDE registry (ALTura Impact on the Treatment of Abdominal Aortic Aneurysms Using a Novel D-stent EVAR Design) is being conducted across a range of UK and international clinical centers to evaluate the use of the Altura Endograf...

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...